Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
RegulatoryNotablemateriality 61 out of 100
What happened
FactPendency of Litigation(s)/dispute(s) or the outcome impacting the Company. Litigation against. litigation is filed.
Why it matters
CapitSignal interpretationLitigation creates a contingent liability that is not in reported profit until it crystallises.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Capex
DelayedEarlierQ2 FY26
The capex incurred during Q2 FY26 was Rs. ~45.6 crore.
NowQ2 FY26
Our salicylic acid operations at Tarapur are stabilizing well with near-term output of around 300 tonnes per month and targeting 500 tonnes per month for Q4 FY26.
Change
FactTimeline delay
Implication
CapitSignal interpretationThe current statement indicates a target for Q4 FY26, which suggests a delay in achieving the previously stated capex goals for Q2 FY26. The focus has shifted to future output targets rather than current capex figures.confidence 90%
Watch next
Fact- Amount claimed against the company
- Whether a provision has been made
- Next hearing or order date
- We expect to make further progress on utilization ramp-up during FY 2027. (management committed by FY27)
- For FY '26, we feel around INR10 crores to INR15 crores might -- of benefit might come in this year itself. (management committed by FY26)
Evidence
- Aarti Drugs Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company(opens the original filing in a new tab)
- Earlier statement · Q2 FY26
- Latest statement · Q2 FY26
- Earlier statement · Q4 FY25
How CapitSignal classified this
- Reasoning:
- LITIGATION base 56; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%